Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report

Abstract Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high programmed death‐ligand 1 (PD‐L1) expressing...

Full description

Bibliographic Details
Main Authors: Hirokazu Taniguchi, Shinnosuke Takemoto, Mutsumi Ozasa, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Takumi Nakao, Kojima Tomohito, Hiroshi Gyotoku, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Junya Fukuoka, Hiroshi Mukae
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
immunotherapy
programmed death‐ligand 1
pulmonary sarcomatoid carcinoma
Online Access:https://doi.org/10.1111/1759-7714.13890

Internet

https://doi.org/10.1111/1759-7714.13890

Similar Items